Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice

被引:85
|
作者
Braunersreuther, Vincent [1 ]
Pellieux, Corinne [1 ]
Pelli, Graziano [1 ]
Burger, Fabienne [1 ]
Steffens, Sabine [1 ]
Montessuit, Christophe [1 ]
Weber, Christian [4 ]
Proudfoot, Amanda [5 ]
Mach, Francois [1 ]
Arnaud, Claire [1 ,2 ,3 ]
机构
[1] Univ Hosp, Fdn Med Res, Dept Med, Div Cardiol, CH-1211 Geneva, Switzerland
[2] INSERM, ERI17, F-38042 Grenoble, France
[3] Univ Grenoble 1, Fac Med, IFR1, F-38042 Grenoble, France
[4] Cardiovasc Mol Biol Inst Aachen, D-52074 Aachen, Germany
[5] Merck Serono Geneva Res Ctr, CH-1202 Geneva, Switzerland
基金
瑞士国家科学基金会;
关键词
Myocardial ischemia; Reperfusion injury; Inflammation; Chemokines; CCL5/RANTES; ISCHEMIA-REPERFUSION; OXIDATIVE STRESS; NEUTROPHILS; RECEPTORS; CCR5; OLIGOMERIZATION; MECHANISMS; MIGRATION; BINDING; MARKERS;
D O I
10.1016/j.yjmcc.2009.07.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although beneficial for cardiomyocyte salvage and to limit myocardial damage and cardiac dysfunction, restoration of blood flow after prolonged ischemia exacerbates myocardial injuries. Several deleterious processes that contribute to cardiomyocyte death have been proposed, including massive release of reactive oxygen species, calcium overload and hypercontracture development or leukocyte infiltration within the damaged myocardium. Chemokines are known to enhance leukocyte diapedesis at inflammatory sites. The aim of the present study was to investigate the effect of chemokine CCL5/RANTES antagonism in an in vivo mouse model of ischemia and reperfusion. ApoE(-/-) mice were submitted to 30 min ischemia, by ligature of the left coronary artery, followed by 24 h reperfusion. Intraperitoneal injection of 10 mu g of CCL5/RANTES antagonist [(44)AANA(47)]-RANTES, 5 min prior to reperfusion, reduced infarct size as well as Troponin I serum levels compared to PBS-treated mice. This beneficial effect of [(44)AANA(47)]-RANTES treatment was associated with reduced leukocyte infiltration into the reperfused myocardium, as well as decreased chemokines Ccl2/Mcp-1 and Ccl3/Mip-1 alpha expression, oxidative stress, and apoptosis. However, mice deficient for the CCL5/RANTES receptor Ccr5 did not exhibit myocardium salvage in our model of ischemia-reperfusion. Furthermore, [(44)AANA(47)]-RANTES did not mediate cardioprotection in these ApoE(-/-) Ccr5(-/-) deficient mice, probably due to enhanced expression of compensatory chemokines. This study provides the first evidence that inhibition of CCL5/RANTES exerts cardioprotective effects during early myocardial reperfusion, through its anti-inflammatory properties. Our findings indicate that blocking chemokine receptor/ligand interactions might become a novel therapeutic strategy to reduce reperfusion injuries in patients during acute coronary syndromes. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:789 / 798
页数:10
相关论文
共 50 条
  • [1] Inhibition of CC chemokine RANTES reduces myocardial reperfusion injuries in atherosclerotic mice
    Braunersreuther, V.
    Arnaud, C.
    Steffens, S.
    Pelli, G.
    Burger, F.
    Proudfoot, A.
    Mach, F.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2008, 38 : 27 - 28
  • [2] Angiogenic properties of the chemokine RANTES/CCL5
    Suffee, Nadine
    Richard, Benjamin
    Hlawaty, Hanna
    Oudar, Olivier
    Charnaux, Nathalie
    Sutton, Angela
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2011, 39 : 1649 - 1653
  • [3] Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5)
    Elliott, MB
    Tebbey, PW
    Pryharski, KS
    Scheuer, CA
    Laughlin, TS
    Hancock, GE
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2004, 73 (02) : 300 - 308
  • [4] IMPORTANCE OF THE CHEMOKINE RANTES (CCL5) FOR FATTY LIVER DISEASE AND OBESITY IN MICE
    Nellen, A.
    Zaldivar, M. Moreno
    Schmitz, P.
    Heinrichs, D.
    Berres, M-L
    Weber, C.
    Trautwein, C.
    Wasmuth, H. E.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S503 - S503
  • [5] The chemokine RANTES (CCL5) is an important mediator of fibrosis in murine and human chronic liver injury
    Berres, M. L.
    Rueland, A.
    Zaldivar, M. Moreno
    Schmitz, R.
    Scholten, D.
    Gassler, N.
    Weber, C.
    Trautwein, C.
    Wasmuth, H. E.
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 : S61 - S61
  • [6] A dual role for tumor-derived chemokine RANTES (CCL5)
    Adler, EP
    Lemken, CA
    Katchen, NS
    Kurt, RA
    [J]. IMMUNOLOGY LETTERS, 2003, 90 (2-3) : 187 - 194
  • [7] Aerobic exercise increases the chemokine RANTES/CCL5 in Parkinson's disease
    Uc, E. Y.
    Neal, M.
    Anantharam, V.
    Murry, D. J.
    Doerschug, K. C.
    Thomsen, T. R.
    Kline, J. N.
    Dawson, J. D.
    Darling, W. G.
    Kanthasamy, A.
    Narayanan, N. S.
    [J]. MOVEMENT DISORDERS, 2015, 30 : S134 - S134
  • [8] PHARMACOLOGICAL ANTAGONISM OF THE CC CHEMOKINE CCL5 (RANTES) BY MET-CCL5 REDUCES LIVER FIBROSIS AND ACCELERATES FIBROSIS REGRESSION AFTER CHRONIC LIVER INJURY IN VIVO
    Berres, Marie-Luise
    Zaldivar, Mirko Moreno
    Heinrichs, Daniel
    Trautwein, Christian
    Wasmuth, Hermann Elard
    [J]. HEPATOLOGY, 2010, 52 (04) : 447A - 447A
  • [9] Involvement of the chemokine RANTES (CCL5) in resistance to experimental infection with Leishmania major
    Santiago, HD
    Oliveira, CF
    Santiago, L
    Ferraz, FO
    de Souza, DD
    De-Freitas, LAR
    Afonso, LCC
    Teixeira, MM
    Gazzinelli, RT
    Vieira, LQ
    [J]. INFECTION AND IMMUNITY, 2004, 72 (08) : 4918 - 4923
  • [10] Tails of the unexpected - an atypical receptor for the chemokine RANTES/CCL5 expressed in brain
    Pease, J. E.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2006, 149 (05) : 460 - 462